Vaginal Cancer

High-grade vulvar, vaginal and anal precancer rates decreased or stabilized after the introduction of the HPV vaccine, according to findings published in the American Journal of Preventive Medicine.

Nivolumab showed promising efficacy among women with recurrent or metastatic cervical, vaginal or vulvar cancers, according to results from the single-arm phase 1/phase 2 CheckMate 358 trial published in Journal of Clinical Oncology.